Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry
Mikkael A. Sekeres(University of Miami), David L. Grinblatt(NorthShore University HealthSystem), Alan F. List(TE Laboratories (Ireland)), Thomas K. Street(Bristol-Myers Squibb (Switzerland)), Arlene S. Swern, Jaroslaw P. Maciejewski(Cleveland Clinic), Rami S. Komrokji(Moffitt Cancer Center), Kristen Sullivan(Tufts University), Mohit Narang(Gettysburg College)
Cited by 5
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k